Literature DB >> 34511893

Bronchodilator Response in Patients with COPD, Asthma-COPD-Overlap (ACO) and Asthma, Evaluated by Plethysmographic and Spirometric z-Score Target Parameters.

Richard Kraemer1,2, Hans-Jürgen Smith3, Fabian Gardin4, Jürg Barandun4, Stefan Minder3, Lukas Kern5, Martin H Brutsche5.   

Abstract

BACKGROUND: Airflow reversibility criteria in COPD are still debated - especially in situations of co-existing COPD and asthma. Bronchodilator response (BDR) is usually assessed by spirometric parameters. Changes assessed by plethysmographic parameters such as the effective, specific airway conductance (sGeff), and changes in end-expiratory resting level at functional residual capacity (FRCpleth) are rarely appreciated. We aimed to assess BDR by spirometric and concomitantly measured plethysmographic parameters. Moreover, BDR on the specific aerodynamic work of breathing (sWOB) was evaluated.
METHODS: From databases of 3 pulmonary centers, BDR to 200 g salbutamol was retrospectively evaluated by spirometric (∆FEV1 and ∆FEF25-75), and plethysmographic (∆sGeff, ∆FRCpleth, and ∆sWOB) parameters in a total of 843 patients diagnosed as COPD (478 = 57%), asthma-COPD-overlap (ACO) (139 = 17%), or asthma (226 = 27%), encountering 1686 BDR-measurement-sets (COPD n = 958; ACO n = 276; asthma n = 452).
RESULTS: Evaluating z-score improvement taking into consideration the whole pre-test z-score range, highest BDR was achieved by combining ∆sGeff and ∆FRC detecting BDR in 62.2% (asthma: 71.4%; ACO: 56.7%; COPD: 59.8%), by ∆sGeff in 53.4% (asthma: 69.1%; ACO: 51.6%; COPD: 47.4%), whereas ∆FEV1 only distinguished in 10.6% (asthma: 21.8%; ACO: 18.6%; COPD: 4.2%). Remarkably, ∆sWOB detected BDR in 49.4% (asthma: 76.2%; ACO: 47.8%; COPD: 46.9%).
CONCLUSION: BDR largely depends on the pre-test functional severity and, therefore, should be evaluated in relation to the pre-test conditions expressed as ∆z-scores, considering changes in airway dynamics, changes in static lung volumes and changes in small airway function. Plethysmographic parameters demonstrated BDR at a significant higher rate than spirometric parameters.
© 2021 Kraemer et al.

Entities:  

Keywords:  ACO; COPD; COPD and coexisting asthma; aerodynamic work of breathing; bronchodilator response; pulmonary hyperinflation; small airways dysfunction

Mesh:

Substances:

Year:  2021        PMID: 34511893      PMCID: PMC8420556          DOI: 10.2147/COPD.S319220

Source DB:  PubMed          Journal:  Int J Chron Obstruct Pulmon Dis        ISSN: 1176-9106


  55 in total

1.  The need to change the method for defining mild airway obstruction.

Authors:  P H Quanjer; P L Enright; M R Miller; J Stocks; G Ruppel; M P Swanney; R O Crapo; O F Pedersen; E Falaschetti; J P Schouten; R L Jensen
Journal:  Eur Respir J       Date:  2011-03       Impact factor: 16.671

Review 2.  Hyperinflation, dyspnea, and exercise intolerance in chronic obstructive pulmonary disease.

Authors:  Denis E O'Donnell
Journal:  Proc Am Thorac Soc       Date:  2006-04

3.  Recommendations for epidemiological studies on COPD.

Authors:  P S Bakke; E Rönmark; T Eagan; F Pistelli; I Annesi-Maesano; M Maly; M Meren; P Vermeire Dagger; J Vestbo; G Viegi; J Zielinski; B Lundbäck
Journal:  Eur Respir J       Date:  2011-12       Impact factor: 16.671

4.  Effect of allergic bronchopulmonary aspergillosis on lung function in children with cystic fibrosis.

Authors:  Richard Kraemer; Natascha Deloséa; Pietro Ballinari; Sabina Gallati; Reto Crameri
Journal:  Am J Respir Crit Care Med       Date:  2006-09-07       Impact factor: 21.405

5.  Association between Functional Small Airway Disease and FEV1 Decline in Chronic Obstructive Pulmonary Disease.

Authors:  Surya P Bhatt; Xavier Soler; Xin Wang; Susan Murray; Antonio R Anzueto; Terri H Beaty; Aladin M Boriek; Richard Casaburi; Gerard J Criner; Alejandro A Diaz; Mark T Dransfield; Douglas Curran-Everett; Craig J Galbán; Eric A Hoffman; James C Hogg; Ella A Kazerooni; Victor Kim; Gregory L Kinney; Amir Lagstein; David A Lynch; Barry J Make; Fernando J Martinez; Joe W Ramsdell; Rishindra Reddy; Brian D Ross; Harry B Rossiter; Robert M Steiner; Matthew J Strand; Edwin J R van Beek; Emily S Wan; George R Washko; J Michael Wells; Chris H Wendt; Robert A Wise; Edwin K Silverman; James D Crapo; Russell P Bowler; MeiLan K Han
Journal:  Am J Respir Crit Care Med       Date:  2016-07-15       Impact factor: 21.405

6.  Bronchodilator responsiveness in patients with COPD.

Authors:  D P Tashkin; B Celli; M Decramer; D Liu; D Burkhart; C Cassino; S Kesten
Journal:  Eur Respir J       Date:  2008-02-06       Impact factor: 16.671

7.  Bronchodilator responsiveness as a phenotypic characteristic of established chronic obstructive pulmonary disease.

Authors:  Paul Albert; Alvar Agusti; Lisa Edwards; Ruth Tal-Singer; Julie Yates; Per Bakke; Bartolome R Celli; Harvey O Coxson; Courtney Crim; David A Lomas; William Macnee; Bruce Miller; Stephen Rennard; Edwin K Silverman; Jørgen Vestbo; Emiel Wouters; Peter Calverley
Journal:  Thorax       Date:  2012-06-13       Impact factor: 9.139

8.  Asthma, COPD and overlap syndrome: a longitudinal study in young European adults.

Authors:  Roberto de Marco; Alessandro Marcon; Andrea Rossi; Josep M Antó; Isa Cerveri; Thorarinn Gislason; Joachim Heinrich; Christer Janson; Deborah Jarvis; Nino Kuenzli; Bénédicte Leynaert; Nicole Probst-Hensch; Cecilie Svanes; Matthias Wjst; Peter Burney
Journal:  Eur Respir J       Date:  2015-06-25       Impact factor: 16.671

9.  Bronchodilator response of advanced lung function parameters depending on COPD severity.

Authors:  Linnea Jarenbäck; Göran Eriksson; Stefan Peterson; Jaro Ankerst; Leif Bjermer; Ellen Tufvesson
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-11-25

10.  Computed Tomography-based Airway Surface Area-to-Volume Ratio for Phenotyping Airway Remodeling in Chronic Obstructive Pulmonary Disease.

Authors:  Sandeep Bodduluri; Abhilash Kizhakke Puliyakote; Arie Nakhmani; Jean-Paul Charbonnier; Joseph M Reinhardt; Surya P Bhatt
Journal:  Am J Respir Crit Care Med       Date:  2021-01-15       Impact factor: 21.405

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.